diethyl cyanomethylphosphonate

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: diethyl cyanomethylphosphonate
• 英文别名: 2-Diethoxyphosphanylacetonitrile
• 化学式: C₆H₁₂NO₂P
• 分子量: 161.141
• InChiKey: IWGBULPPFXIIAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  diethyl cyanomethylphosphonate 、 1-三苯甲基咪唑-4-甲醛 在 sodium amide 作用下， 以 四氢呋喃 为溶剂， 以92%的产率得到1-trityl-4-(2-cyanoethyl)imidazole
  参考文献：
  名称：

  Adger, Brian M.; Surtees, John, Synthetic Communications, 1987, vol. 17, # 2, p. 223 - 228

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED 1H-IMIDAZO [1, 2-B] PYRAZOLE-3-CARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS<br/>[FR] 1H-IMIDAZO[1, 2-B]PYRAZOLE-3-CARBOXAMIDE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：UNIV HENAN NORMAL

  公开号：WO2022012550A1

  公开（公告）日：2022-01-20

  This application discloses a series of substituted 1H-imidazo [1, 2-b] pyrazole-3-carboxamide compounds represented by formula I as kinase inhibitors, in particular BTK (Bruton's Tyrosine Kinase) inhibitors, and the methods of making and using the same for the treatment of autoimmune disease, inflammatory disease, cancer and potentially allergies.

  该应用程序披露了一系列以式I表示的取代的1H-咪唑[1,2-b]吡唑-3-羧酰胺化合物，作为激酶抑制剂，特别是BTK（布鲁顿氏酪氨酸激酶）抑制剂，并且揭示了制备和使用这些化合物用于治疗自身免疫疾病、炎症性疾病、癌症和潜在过敏症的方法。
• METHOD FOR PREPARING ROSUVASTATIN SODIUM
  申请人：FUDAN UNIVERSITY

  公开号：US20170183314A1

  公开（公告）日：2017-06-29

  The present invention belongs to the technical field of organic chemistry, and specifically relates to a method for preparing rosuvastatin sodium. The method of the invention comprises: reducing 4-p-fluorophenyl-6-isopropyl-2-(N-methyl-methylsulfonylamino)pyrimidine-5-carboxylic acid (VII) in the presence of a borohydride, an alkyl-substituted chlorosilane and an assistance in an organic solvent to prepare 4-p-fluorophenyl-5-hydroxymethyl-6-isopropyl-2-(N-methyl-methylsulfonylamino) pyrimidine (VIII); then performing a reaction of the compound VIII with a triphenyl phosphonium salt in an organic solvent to prepare a ((4-p-fluorophenyl-6-isopropyl-2-(N-methyl-methylsulfonylamino)-5-pyridyl)-methyl)triphenyl phosphonium salt (IX); performing a stereoselective Michael addition reaction of (S)-trans-4,5-dihydroxy-pent-2-olefine acid ester (II) with furfural (III) to prepare a 2-((4R,6S)-2-(furan-2-yl)-6-hydroxymethyl-1,3-dioxane-4-yl)acetate (IV); oxidizing the compound IV to prepare a 2-((4R,6S)-2-(furan-2-yl)-6-formacyl-1,3-dioxane-4-yl)acetate (V); performing an olefination reaction of the compound V with the (4-p-fluorophenyl-6-isopropyl-2-(N-methyl-methylsulfonylamino)pyrimid-5-yl)-methyl triphenyl substituted phosphonium salt (IX) or phosphate to prepare 2-((4R,6S)-6-(trans-2-(4-p-fluorophenyl-6-isopropyl-2-(N-methyl-methylsulfonylamino)pyrimid-5-yl)vinyl)-2-(furan-2-yl)-1,3-dioxane-4-yl)acetate (VI); and performing deprotection and sodium salt formation of compound VI to prepare rosuvastatin sodium (I). The method has easily obtainable raw materials, and is simple to operate and suitable for industrial productions.

  本发明属于有机化学技术领域，具体涉及一种制备罗舒伐他汀钠的方法。该发明的方法包括：在有机溶剂中存在硼氢化物、烷基取代氯硅烷和辅助剂的情况下，还原4-对氟苯基-6-异丙基-2-(N-甲基-甲磺胺基)嘧啶-5-羧酸（VII）以制备4-对氟苯基-5-羟甲基-6-异丙基-2-(N-甲基-甲磺胺基)嘧啶（VIII）；然后在有机溶剂中，将化合物VIII与三苯基磷酸盐反应以制备((4-对氟苯基-6-异丙基-2-(N-甲基-甲磺胺基)-5-吡啶基)-甲基)三苯基磷酸盐（IX）；将(S)-反式-4,5-二羟基-戊-2-烯酸酯（II）与呋喃醛（III）进行立体选择性的迈克尔加成反应以制备2-((4R,6S)-2-(呋喃-2-基)-6-羟甲基-1,3-二氧杂环己-4-基)醋酸酯（IV）；将化合物IV氧化以制备2-((4R,6S)-2-(呋喃-2-基)-6-甲酰基-1,3-二氧杂环己-4-基)醋酸酯（V）；将化合物V与(4-对氟苯基-6-异丙基-2-(N-甲基-甲磺胺基)嘧啶-5-基)-甲基三苯基取代磷酸盐（IX）或磷酸盐进行烯化反应以制备2-((4R,6S)-6-(反式-2-(4-对氟苯基-6-异丙基-2-(N-甲基-甲磺胺基)嘧啶-5-基)乙烯基)-2-(呋喃-2-基)-1,3-二氧杂环己-4-基)醋酸酯（VI）；并对化合物VI进行去保护和钠盐形成以制备罗舒伐他汀钠（I）。该方法原料易得，操作简单，适用于工业生产。
• [EN] NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DE N'-HYDROXYCARBAMIMIDOYL -1,2,5-OXADIAZOLE SUBSTITUÉS EN TANT QU'INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE (IDO)
  申请人：MERCK SHARP & DOHME

  公开号：WO2018044663A1

  公开（公告）日：2018-03-08

  Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

  本文揭示了化合物的化学式(I)，或其药学上可接受的盐：化学式(I)。本文还揭示了所述化合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。本文还揭示了包含所述化合物的组合物。本文还揭示了所述组合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。
• [EN] METHODS OF PROPHYLAXIS AND TREATMENT OF CORONA VIRUS<br/>[FR] MÉTHODES DE PROPHYLAXIE ET DE TRAITEMENT DU CORONAVIRUS
  申请人：ESFAM BIOTECH PTY LTD

  公开号：WO2022020891A1

  公开（公告）日：2022-02-03

  The present invention relates to a method of prophylaxis or treatment of Corona virus infection in a subject the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

  本发明涉及一种预防或治疗冠状病毒感染的方法，该方法包括向受试者施用公式（I）化合物的治疗有效量。
• PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR
  申请人：Incyte Corporation

  公开号：US20170015674A1

  公开（公告）日：2017-01-19

  This invention relates to processes and intermediates for making 1-1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.

  这项发明涉及用于制备1-1-[3-氟-2-(三氟甲基)异烟酰基]哌啶-4-基}-3-[4-(7H-吡咯[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]氮杂环戊烷-3-基}乙腈的工艺和中间体，该化合物可用于治疗与Janus激酶（JAK）活性相关的疾病，包括炎症性疾病、自身免疫性疾病、癌症和其他疾病。